MintNeuro

Developing low-power integrated circuits for implantable neural devices and brain-computer interfaces.

Cover Block

Publicly reported

Field	Value
Company	MintNeuro
Tagline	Developing low-power integrated circuits for implantable neural devices and brain-computer interfaces.
Headquarters	Hammersmith, London, UK [Crunchbase, retrieved 2024]
Founded	2023 [Crunchbase, retrieved 2024]
Stage	Seed [Crunchbase, retrieved 2024]
Business model	B2B
Industry	Deeptech
Technology	Hardware
Geography	Western Europe
Growth profile	Venture Scale
Founding team	Co-Founders (3+) [Imperial College London, Nov 2023]
Funding label	Seed
Total disclosed funding	~$5,000,000 [PR Newswire, Aug 2026]

Summary and Signal

PUBLIC MintNeuro is building low power integrated circuits for implantable neural devices, a position that merits attention because it sits upstream of the current wave of brain computer interface and neurostimulation development rather than competing as a full stack device company [Imperial College London, Nov 2023] [MintNeuro, retrieved 2024]. The company emerged from Imperial College London research and spinout activity, with the operating formation described publicly in 2023 and key leadership roles in place from April 2022 as the spinout process began [Imperial College London, Nov 2023].

The commercial thesis is relatively clear in public materials: MintNeuro is developing a modular semiconductor platform with purpose built sensing and stimulation ICs for neural implants, and its stated customers are medical device companies and system integrators building active implantable devices and BCIs [Neurofounders, May 2026] [MintNeuro, retrieved 2024]. That is an interesting wedge because the differentiation appears to rest on function specific, ultra low power silicon intended to reduce size and energy demands in implantable systems, which is a harder technical layer than application software and, if validated, could become embedded deep in partner products [LinkedIn, Dec 2023] [Neurofounders, May 2026].

The team is one of the stronger parts of the public record. Chief executive Dorian Haci, CTO Timothy G. Constandinou, CSO Andrew Jackson, and co founder Tim Denison collectively bring neural interface electronics, integrated circuit research, and academic neurotechnology credentials tied to Imperial and Newcastle University, which fits the company's technical ambition [Imperial College London, Nov 2023] [Imperial College London, retrieved 2026].

On capital formation, the public record points to a November 2023 seed financing of $1.27 million, described by Imperial as a £1 million investment round, followed by a reported $5 million seed round announced in August 2026 [Imperial College London, Nov 2023] [PR Newswire, Aug 2026]. Separately, MintNeuro has been associated with a £1.4 million NIHR grant and £17 million across three ARIA backed projects with partners, which strengthens the technical development picture but should not be read as equivalent to company revenue or unrestricted equity capital [Imperial College London, Nov 2023].

Over the next 12 to 18 months, the main items to watch are whether partner activity converts into repeatable commercial design wins, whether the Motif Neurotech collaboration progresses beyond announcement stage, and whether the current hiring around ASIC validation, mixed signal IC design, and program management translates into visible product and clinical integration milestones [Neurofounders, May 2026] [MintNeuro, retrieved 2024]. The public evidence supports a credible deeptech platform company with a serious technical founding base, while leaving open the central investor questions on sales cycle length, regulatory coupling, and how quickly chip level adoption turns into durable revenue.

One source, partially checked -- Relies on Imperial College London, MintNeuro, Neurofounders, PR Newswire, and LinkedIn; several core company and product claims remain company or partner disclosed rather than independently corroborated.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2B
Industry / Vertical	Deeptech
Technology Type	Hardware
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Seed, total disclosed ~$5,000,000

Company Overview

PUBLIC The company appears to have taken shape before it formally showed up in public startup databases. Imperial College London described MintNeuro as a spinout process that began in April 2022, when Dorian Haci, Timothy G. Constandinou, and Andrew Jackson stepped into chief executive, chief technology, and chief scientific roles respectively, while Crunchbase lists the company as founded in 2023 [Crunchbase, retrieved 2024]. That sequencing matters because it suggests the business emerged from an academic commercialization effort first and only later hardened into a venture-backed company record. MintNeuro is headquartered in Hammersmith, London, and presents itself as a developer of low-power integrated circuits for implantable neural devices and brain-computer interfaces [Crunchbase, retrieved 2024] [mintneuro.com, retrieved 2024].

The public milestone trail is short but coherent. By late 2023, the company had announced a £1 million investment round and highlighted a £1.4 million collaborative NIHR grant alongside three ARIA-backed projects on chip-scale neurotechnology, according to its website [mintneuro.com, retrieved 2024]. Its website also positions the business as a supplier to medical-device companies and system integrators rather than a direct therapeutic-device company, which helps explain the semiconductor-platform framing used across its materials [mintneuro.com, retrieved 2024]. In public terms, this still looks like an early commercial-stage spinout: a defined category, a named London base, and a milestone record anchored more in financing and research programs than in disclosed customer deployments [Crunchbase, retrieved 2024] [mintneuro.com, retrieved 2024].

Well sourced -- Confirmed by Crunchbase and the company website.

The Product and the Stack

MIXED MintNeuro is building at the component layer rather than as a full-stack device company. Public materials describe a modular semiconductor platform made up of purpose-built sensing and stimulation integrated circuits for neural implants, aimed at medical-device companies and system integrators developing active implantable devices and brain-computer interfaces [Neurofounders, May 2026] [MintNeuro]. That positioning matters because it narrows the technical claim: the company is not publicly presenting itself as the therapeutic product owner, but as the silicon supplier intended to make implantable systems smaller, more capable, and more energy-efficient through function-specific ultra-low-power chip design [LinkedIn, Dec 2023] [Neurofounders, May 2026].

The evidence on end use is directionally strong, even if commercial maturity is less clear. MintNeuro's website ties the platform to neurological applications including epilepsy, movement disorders, depression, and related conditions, while Imperial College London links the underlying research base to a wireless intracranial neuromonitoring device for drug-resistant epilepsy through a £1.4 million NIHR-supported collaboration with Imperial and King's College London [MintNeuro] [Imperial College London, Nov 2023]. A separate May 2026 partnership announcement with Motif Neurotech states that MintNeuro's neural-interface chips will be combined with Motif's implant platform for therapeutic brain-computer interfaces in mental health, which supports real ecosystem relevance but does not, on the public record, establish commercial deployment or regulatory clearance [Neurofounders, May 2026].

The most useful public signal on technical stack comes from hiring. Current and archived careers pages point to post-silicon ASIC bring-up, PCB and embedded-system design, circuit characterization, electronic testing, data analysis, and mixed-signal IC design for implantable medical devices, all of which fit the company's stated semiconductor wedge (inferred from job postings) [MintNeuro, retrieved 2024]. That does not prove product readiness by itself, but it does corroborate that MintNeuro is operating as an applied neural-interface chip developer, not only an academic research vehicle [Imperial College London, Nov 2023] [MintNeuro, retrieved 2024].

One source, partially checked -- Product architecture and partnership details are supported by company materials, Imperial College London coverage, hiring pages, and a partner announcement, but several capability claims remain company-led or only partially corroborated.

The Market They Are Entering

Market context

PUBLIC The market matters now because neurotechnology has moved out of pure academic inquiry and into a supply-chain buildout, where the limiting factor is often not the clinical idea but the availability of miniaturized, low-power electronics that can sit inside implantable systems [Imperial College London, Nov 2023] [MintNeuro, retrieved 2024].

Public source material here is thin on formal market sizing, so the cleaner way to frame demand is through adjacent, evidenced markets rather than to force a top-down TAM. MintNeuro positions itself as a component supplier to medical-device companies and system integrators building active implantable medical devices and brain-computer interfaces, not as a direct therapeutic-device vendor [MintNeuro, retrieved 2024]. That places it in an enabling layer of the neurotechnology stack, where demand depends on whether device makers need custom sensing and stimulation ICs to shrink form factor, reduce power draw, and improve implant capability [Neurofounders, May 2026] [LinkedIn, Dec 2023].

The strongest public demand signals are programmatic rather than commercial. Imperial College London reported a £1.4 million NIHR grant involving MintNeuro, Imperial, and King’s College London for a wireless intracranial neuromonitoring device, and £17 million across three ARIA-backed projects advancing chip-scale neurotechnologies toward clinical adoption [Imperial College London, Nov 2023]. Those awards do not establish end-market revenue, but they do indicate that UK public funding bodies see implantable neuroelectronics as an active development priority rather than a speculative edge case [Imperial College London, Nov 2023].

Segment	Public sizing signal	Relevance to MintNeuro
NIHR collaborative neuromonitoring project	£1.4M grant [Imperial College London, Nov 2023]	Evidence of funded demand for implantable neural monitoring electronics
ARIA-backed chip-scale neurotechnology projects	£17M across 3 projects [Imperial College London, Nov 2023]	Suggests institutional support for clinical translation of neurotech hardware
MintNeuro disclosed equity financing	$5M seed round [PR Newswire, Aug 2026]	Indicates investor appetite for enabling neurotech infrastructure

The table is not a market-size model. It is a record of where capital is visibly entering the category, which, for a pre-scale semiconductor startup, is often the more useful near-term signal than a broad headline TAM.

Demand drivers and adjacent markets

PUBLIC The immediate tailwind is the push to make neural implants smaller and more energy-efficient, because device performance in this category is constrained by heat, battery life, implant size, and long-term biocompatible packaging requirements [LinkedIn, Dec 2023] [Neurofounders, May 2026].

MintNeuro’s public wedge, function-specific ultra-low-power silicon, lines up with that constraint set [LinkedIn, Dec 2023]. If device developers are moving away from general-purpose electronics toward application-specific architectures for sensing and stimulation, then a specialist IC supplier can become relevant across several indications without carrying full therapeutic-development risk itself [Neurofounders, May 2026]. That is the strategic appeal of the category.

The adjacent markets are broader than brain-computer interfaces alone. MintNeuro’s own materials cite applications in epilepsy, movement disorders, depression, and other neurological conditions, while the Motif Neurotech partnership points specifically to therapeutic BCIs for mental health [MintNeuro, retrieved 2024] [Medical Device Network, May 2026]. In practical terms, that means the company sits at the intersection of implantable medical devices, neurostimulation, neuromonitoring, and BCI tooling. Those are related but not identical markets, and each brings different buying centers, clinical timelines, and regulatory burdens.

There is also a substitute-market question worth stating plainly. Some neurodevice developers may prefer to build electronics in-house or source from larger analog and mixed-signal semiconductor vendors rather than rely on a startup supplier. Public sources do not show how large that substitution risk is for MintNeuro specifically, but the existence of a partnership model, rather than a finished-device model, implies the company is betting that enough developers want external, purpose-built chip support to justify an independent supplier layer [Neurofounders, May 2026] [MintNeuro, retrieved 2024].

Regulatory and macro forces

PUBLIC Regulation is a market driver here because implantable neurotechnology only becomes a real purchasing category when clinical translation looks feasible.

The public evidence suggests that government-backed translational programs are helping de-risk that path. Imperial ties MintNeuro’s progress to NIHR and ARIA-supported projects aimed at wireless neuromonitoring and the clinical adoption of chip-scale neurotechnologies [Imperial College London, Nov 2023]. That matters because it links the company to funding environments that reward medical relevance, engineering rigor, and eventual deployment pathways, rather than research novelty alone.

The macro constraint is time. Hardware development for active implantable devices typically requires long validation cycles, systems integration, and coordination with partners that control the final regulatory submission. Public materials do not provide revenue, deployment counts, or regulatory milestones for MintNeuro, so the market case should be read as a medium-term infrastructure build rather than a short-cycle commercial ramp [MintNeuro, retrieved 2024] [Neurofounders, May 2026]. The market may be attractive, but adoption is still gated by clinical and device-manufacturer timelines.

One source, partially checked -- Section relies primarily on Imperial College London, MintNeuro, PR Newswire, LinkedIn, and Neurofounders. Public funding signals are cited, but no independent third-party TAM report or direct commercial market-size dataset was available in the provided research.

The Competitive Field

MIXED MintNeuro sits lower in the neurotechnology stack than most of the names that dominate public attention, positioning itself as a chip supplier to implant developers rather than as a full-stack clinical device company [MintNeuro, retrieved 2024] [Neurofounders, May 2026].

Company	Positioning	Stage / Funding	Notable Differentiator	Source
MintNeuro	Low-power integrated circuits for implantable neural devices and brain-computer interfaces, sold to medical-device companies and system integrators	Seed; disclosed funding includes a £1 million investment round in 2023 and a $5 million raise announced in 2026	Modular semiconductor platform with purpose-built sensing and stimulation ICs; commercial model centers on enabling other device makers rather than building the end therapy	[Imperial College London, Nov 2023] [PR Newswire, Aug 2026] [Neurofounders, May 2026] [MintNeuro, retrieved 2024]
Neuralink	Brain-computer interface developer building implant systems directly	Funding detail not included in the structured facts	Full-stack device approach, including the implant system itself rather than a component-supplier model	[Crunchbase, retrieved 2024]
Paradromics	Brain-computer interface developer	Funding detail not included in the structured facts	Competes at the device platform level, not the semiconductor component level	[Crunchbase, retrieved 2024]
Synchron	Brain-computer interface developer	Funding detail not included in the structured facts	Clinical and commercial focus on a complete BCI pathway rather than merchant silicon	[Crunchbase, retrieved 2024]
Precision Neuroscience	Neural interface company	Funding detail not included in the structured facts	Competes through a broader neural-interface system ambition rather than as an enabling chip vendor	[Crunchbase, retrieved 2024]

The table points to a useful distinction. MintNeuro is not competing head-on for every budget line that funds Neuralink, Paradromics, Synchron, or Precision Neuroscience, because those companies are developing recognizable device programs and, in public materials, present themselves as system builders rather than specialist chip suppliers [Crunchbase, retrieved 2024] [MintNeuro, retrieved 2024]. That creates three practical segments: incumbent semiconductor vendors that could serve implant developers with general-purpose or adapted components, venture-backed BCI and neurostimulation challengers building complete systems, and adjacent substitutes such as in-house ASIC development inside larger device programs. MintNeuro's offering, according to its website and partnership materials, is meant to sit inside those programs as a specialist layer for sensing and stimulation electronics [MintNeuro, retrieved 2024] [Neurofounders, May 2026].

Where the company appears strongest today is in technical specialization and founder-market fit. Imperial identifies co-founders Timothy G. Constandinou, Andrew Jackson, Tim Denison, and CEO Dorian Haci as emerging from neural-interface and bioelectronics research tied to Imperial and allied institutions, which matters in a market where chip design, implant constraints, and translational neuroscience need to line up early [Imperial College London, Nov 2023] [Imperial College London, retrieved 2026]. The grant record also supports that reading: a £1.4 million NIHR-backed collaboration and £17 million across three ARIA-linked projects suggest the team is operating in research and translational networks that are hard to assemble quickly [Imperial College London, Nov 2023]. That edge is real but not fully durable. Academic access and application-specific IC expertise can compound, but they are more perishable than regulatory clearance, installed clinical channels, or long-term supply agreements.

The main exposure is that the companies named as competitors control more of the downstream narrative and, in some cases, likely more of the clinical roadmap. A device company such as Synchron or Neuralink can define product requirements, own physician and trial relationships, and decide whether to buy specialist chips, adapt merchant silicon, or develop custom electronics internally [Crunchbase, retrieved 2024]. MintNeuro's public partnership with Motif Neurotech is encouraging because it validates the supplier model, but the announcement does not disclose contract value, exclusivity, or deployment scale [Neurofounders, May 2026]. That leaves the company exposed to two familiar risks for deeptech component vendors: design-in cycles are long, and the customer can remain structurally more powerful than the supplier.

Over the next 18 months, the most plausible competitive outcome is not a single company taking the whole category, but a sorting between platform owners and specialist enablers. MintNeuro is a winner if more neurotech developers conclude that purpose-built low-power ICs are worth outsourcing and if partnerships like the Motif Neurotech relationship convert into repeat design wins [Neurofounders, May 2026] [MintNeuro, retrieved 2024]. Neuralink is a winner if the market continues to reward vertically integrated programs that keep the silicon, device, and clinical stack under one roof [Crunchbase, retrieved 2024]. In the same scenario, a likely loser is any merchant-silicon supplier, including MintNeuro, if device makers decide custom chip work should stay internal or be concentrated among a very small set of strategic partners.

One source, partially checked -- Based primarily on company materials, Imperial College London reporting, Neurofounders partnership coverage, and competitor identification from Crunchbase; competitor funding and operating detail were not independently established within the provided sources.

Opportunity

Upside Case

PUBLIC The prize here is unusually large for a seed-stage semiconductor spinout: if MintNeuro becomes the preferred chip supplier for implantable neurotechnology, it could sit beneath multiple device categories rather than trying to win a single therapy market [MintNeuro, retrieved 2024] [Neurofounders, May 2026].

The headline opportunity is not that MintNeuro builds the next branded brain-computer interface on its own. The more interesting outcome is that it becomes an enabling layer for other device makers, supplying purpose-built sensing and stimulation ICs into a market where size, power draw, and implant constraints matter enough that off-the-shelf electronics can be a limiting factor, according to the company and partner materials [MintNeuro, retrieved 2024] [Neurofounders, May 2026] [LinkedIn, Dec 2023]. That outcome is reachable, not merely aspirational, because the public record already shows three ingredients that matter in deeptech commercialization: a founding team with relevant neural-interface and IC expertise tied to Imperial College London and Newcastle University [Imperial College London, Nov 2023], non-dilutive support through a £1.4 million NIHR grant and ARIA-backed projects totaling £17 million at the project level [Imperial College London, Nov 2023], and at least one named ecosystem partnership with Motif Neurotech aimed at combining MintNeuro chips with a clinical-stage implant platform [Neurofounders, May 2026]. None of that proves scaled revenue, but it does suggest the company is being pulled toward real device programs rather than remaining a lab-only effort.

Scenario	What happens	Catalyst	Why it's plausible
Foundational supplier to neuro implant OEMs	MintNeuro becomes a repeat chip partner for device developers in epilepsy, movement disorders, mental health, and adjacent neurostimulation programs	More partnerships like the Motif Neurotech agreement, where MintNeuro supplies the neural-interface chip layer into third-party implant systems [Neurofounders, May 2026]	The company is positioning itself as a B2B semiconductor supplier to medical-device companies and system integrators, not a direct-to-patient device brand [MintNeuro, retrieved 2024]
Clinical program pick-and-shovel provider	MintNeuro's IC platform is adopted across funded translational and clinical research programs, creating a pipeline into later commercial devices	Progress from NIHR-supported and ARIA-supported projects into device architectures that require low-power custom silicon [Imperial College London, Nov 2023]	The public record shows grant-backed work in wireless intracranial neuromonitoring and chip-scale neurotechnologies, which is consistent with early platform insertion before full commercial launch [Imperial College London, Nov 2023]
European neurotech design standard	MintNeuro becomes a default design choice for smaller Western European neurotech companies that lack in-house mixed-signal implant IC capability	Continued hiring in ASIC validation, mixed-signal IC design, and program management, indicating productization capacity [MintNeuro, retrieved 2024]	The careers pages show active hiring for core semiconductor and delivery roles, which is the profile of a company trying to move from research into repeat development work [MintNeuro, retrieved 2024]

The compounding dynamic, if it appears, is design-in lock-in rather than a consumer-style network effect. Implantable-device developers face long product cycles, technical validation burdens, and meaningful switching costs once a custom chip path is integrated into a system architecture, which means one successful program can lead to follow-on generations, adjacent indications, and referenceability across a narrow but valuable customer set. The early signs are still modest, but they are visible: MintNeuro is presenting a modular platform rather than a one-off chip [Neurofounders, May 2026], it is hiring for ASIC validation and mixed-signal IC design roles that fit repeat product development [MintNeuro, retrieved 2024], and it has already attached itself to academic, translational, and partner-led programs that can seed future commercial demand [Imperial College London, Nov 2023] [Neurofounders, May 2026]. In hardware, especially medtech-adjacent hardware, this kind of wedge can compound slowly and then matter all at once.

The size of the win is easiest to frame by category position rather than near-term revenue arithmetic. Public sources in this research set do not provide a verified neurotech TAM, and they do not support a grounded valuation model for MintNeuro today. Still, if the "foundational supplier to neuro implant OEMs" scenario plays out, the company could resemble a scarce picks-and-shovels asset inside neurotechnology, with value driven by design wins across several device companies rather than one therapeutic bet (scenario, not a forecast) [MintNeuro, retrieved 2024] [Neurofounders, May 2026]. The reason investors pay attention to that shape is simple: platform suppliers that become embedded in regulated hardware stacks can earn strategic value disproportionate to their size, particularly when their technology helps shrink power budgets and device footprints in clinically relevant applications such as epilepsy and other neurological conditions cited by the company and its academic backers [MintNeuro, retrieved 2024] [Imperial College London, Nov 2023].

One source, partially checked -- Built primarily from Imperial College London reporting, MintNeuro public materials, LinkedIn posts, and a partnership announcement; upside framing is analytical and conditional rather than validated by commercial traction disclosures.

Sources